Currently, three PARP inhibitors are FDA approved for use in patients with ovarian cancer –olaparib (AstraZeneca), rucaparib (Clovis), and niraparib (GlaxoSmithKline) (Table 1). This evidence concerns the gene PARP1 and ovarian carcinoma.